• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Finaalll dr. redddy
 

Finaalll dr. redddy

on

  • 518 views

 

Statistics

Views

Total Views
518
Views on SlideShare
518
Embed Views
0

Actions

Likes
0
Downloads
49
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Finaalll dr. redddy Finaalll dr. redddy Presentation Transcript

    • DR. REDDY’S LAB BY TEJASVI YADAV
    • Overview of Pharmaceutical Industry in India
    •  The Pharmaceutical Industry in India is one of the largest in the world. It ranks 4th in the world, pertaining to the volume of sales. The estimated worth of the Indian Pharmaceutical Industry is US$ 6billion. In 2008, the domestic pharmaceuticals market in India was expected to be US$ 10.76 billion and this is likely to increase at a compound annual growth rate of 9.9 per cent until 2010 and subsequently at 9.5per cent till the year 2015. The Indian Pharmaceutical Industry is one of the biggest producers of the active Pharmaceutical ingredients (API) in the international arena.
    • Contribution of Pharmaceutical Industry toIndian GDP
    • The Indian Pharmaceuticals Industry includes smallscaled, medium scaled, large scaled players, whichtotals nearly 300different companies.There are several other small units operating in thedomestic sector. The sales of the Indian Pharmaceutical Industrywould be worth US$ 43billion within the next decade.The Pharmaceuticals Industry in India producesaround 20%to 24% of the global generic drugs.
    • Dr.REDDY’S LAB ►ESTABLISHED IN 1984 Dr.ANJI REDDYDoctorate from the national chemical laboratory,puneTOP PHARMACEUTICAL COMPANY IN THE COUNTRY
    • Established in 1984, Dr. Reddy·s Laboratories (NYSERDY) is anemerging global pharmaceutical company.Dr. Reddy·s products are marketed globally, with a focus on India, US,europe and Russia.Dr. Reddy·s conducts research in the areas of metabolic disorders,cardiovascular indications, anti-infective and inflammationThe company has 60 active pharmaceutical ingredients tomanufacture drugs, critical care products, diagnostic kits andbiotechnology products.The company has 6 FDA plants that produce active pharmaingredients and 7 FDA inspected and ISO 9001 and ISO 14001certifiedplants.
    • ACHIEVEMENTSPadma shri in 2001.Dr. K. Anji reddy is also a philanthropist.Dr. K. Anji reddy has received many awards and honors
    • ► 7500 employees working across the globe in more than 35 countriesMD----SATISH KUMAR TURNOVER OF RS. 537.70 CRORES
    • TOP COMPANIES♣ RANBAXY LABORATORIES♣ CIPLA♣ DR.REDDYS LABORATORIES♣ NICHOLAS PIRAMAL♣ AUROBINDO PHARMA♣ LUPIN♣ CADILA HEALTHCARE♣ SUN PHARMACEUTICAL♣ WOCKHARDT and♣ ORCHID CHEMICAL
    • HIS QUALITIES► Great man with the determination.► Brave man who works while others sleep► Thinking is the capital enterprise►Sweat for the great vision
    • ► 1300 people in the campus recruitment.► 1/3 is the women►“Mr Prabir Kumar Jha, Senior Vice- President and Global Head of Human Resources” said the information.
    • PRODUCTS OF DR. REDDY
    • SHARE PRICE on 05.10.2012In NSE share price of Dr. reddy is 1697.30IN BSE share price of Dr. reddy is 1693.30
    • Dr. Reddy·s Position in Indian Market
    • Dr Reddys Laboratories remained on top with consolidatednet sales of Rs 5,283 crore during the nine months endedDecember 2009 as against Rs 4,862 crore in the same periodof last year indicating a relatively lower growth of 8.7 per cent.Dr. Reddy·s forayed into the rural markets in FY09 withlaunch of an exclusive portfolio of products targeted at theneeds of people in rural India.Adjusted EBITDA of Rs. 15,828 million is highest amongpharmaceutical companies in India in the year 2009-10.In 2009-10, share of revenue from the internationalbusinesses stood at 82%, with 18% coming from India.
    • Ratio analysis Year 2012 2011 2010 2009 Current 1.7 1.66 1.49 1.85 RatioQuick Ratio 1.84 1.91 1.45 2.13Debt Equity 0.23 0.24 0.1 0.12 Ratio
    • Dr Reddys Laboratories remained on top with consolidatednet sales of Rs 5,283 crore during the nine months endedDecember 2009 as against Rs 4,862 crore in the same periodof last year indicating a relatively lower growth of 8.7 per cent.Dr. Reddy·s forayed into the rural markets in FY09 withlaunch of an exclusive portfolio of products targeted at theneeds of people in rural India.Adjusted EBITDA of Rs. 15,828 million is highest amongpharmaceutical companies in India in the year 2009-10.In 2009-10, share of revenue from the internationalbusinesses stood at 82%, with 18% coming from India.
    • PROFITABILITY RATIOS 2012 2011Profit margin 17.42 24.76Return on assets 286.12 350.30Return on equity 10.55 15.87Assets turnover 1.97 1.86Earning per share 28.26 50.11
    • Thank you